CN113917017A - Application of chiral gold nanoparticles in improving content of short-chain fatty acids in intestinal tract - Google Patents
Application of chiral gold nanoparticles in improving content of short-chain fatty acids in intestinal tract Download PDFInfo
- Publication number
- CN113917017A CN113917017A CN202111165514.9A CN202111165514A CN113917017A CN 113917017 A CN113917017 A CN 113917017A CN 202111165514 A CN202111165514 A CN 202111165514A CN 113917017 A CN113917017 A CN 113917017A
- Authority
- CN
- China
- Prior art keywords
- gold nanoparticles
- chiral
- short
- chain fatty
- fatty acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Medicinal Preparation (AREA)
- Manufacture Of Metal Powder And Suspensions Thereof (AREA)
Abstract
The invention discloses an application of chiral gold nanoparticles in improving the content of short-chain fatty acids in intestinal tracts, wherein the modified chiral gold nanoparticles are used for promoting the generation of short-chain fatty acids such as acetic acid, propionic acid, butyric acid, isovaleric acid and the like in a stomach irrigation mode, and the increase of the short-chain fatty acids can be regulated and controlled by controlling the chiral strength of the chiral gold nanoparticles; in addition, the modified chiral gold nanoparticles have good biocompatibility and stability, do not damage organisms, and have good application prospects in treatment of intestinal diseases, immune diseases and the like.
Description
Technical Field
The invention relates to the field of nano materials, in particular to application of chiral gold nanoparticles in improving the content of short-chain fatty acids in intestinal tracts.
Background
Short Chain Fatty Acids (SCFA) are metabolites produced by beneficial bacteria in the gut to metabolize carbohydrates such as dietary fiber, and are essential for gut health and body health, mainly including acetic acid, propionic acid, isobutyric acid, butyric acid, isovaleric acid, valeric acid. Short chain fatty acids have a key role in regulating the immune system, host metabolism, cell proliferation, and the like. Acetic acid, the highest percentage of short chain fatty acids produced by intestinal bacteria, helps to keep the intestinal environment stable and to nourish other beneficial bacteria in the colon. Butyrate plays a crucial role in combating inflammation and is important for both digestive health and disease prevention. Propionate can reduce cholesterol and reduce fat storage, and has antiinflammatory and anticancer effects. Therefore, increasing the content of short chain fatty acids in the intestinal tract can improve the intestinal health and physical and psychological health.
Chiral nanomaterials have attracted extensive attention in the fields of chiral catalysis, enantiomer-specific separation, sensing, biomedicine and the like because of their chiral optical properties and hand shape recognition ability. In recent years, nanoparticles have been reported to have an effect of improving tumors, thrombi, inflammations, and neurodegenerative diseases by means of administration such as tail vein injection, subcutaneous injection, and in situ injection. However, the use of such a dietary supplement as a drug for improving intestinal short-chain fatty acids by gavage to treat diseases has not been studied yet, and the effect of the chiral property of the nanomaterial has been reported.
Disclosure of Invention
The invention provides application of chiral gold nanoparticles in improving the content of short-chain fatty acid with intestinal tract performance.
The invention provides the following technical scheme:
the invention provides application of chiral gold nanoparticles in improving the content of short-chain fatty acids in intestinal tracts.
Further, the chiral nanoparticles are in D-form and/or L-form.
Further, the short chain fatty acids include one or more of acetic acid, propionic acid, butyric acid, and isovaleric acid.
Further, for the chiral gold nanoparticles with the same configuration, when the anisotropy factor is 0< g ≤ 0.2, the increase of the short-chain fatty acid in the intestinal tract increases with the increase of the g value.
Further, the chiral gold nanoparticles are synthesized by the following steps:
(1) reacting NaBH4Dissolving in water, sequentially adding HAuCl4Reacting with a Cetyl Trimethyl Ammonium Bromide (CTAB) aqueous solution to obtain a seed 1;
(2) to HAuCl4Adding trisodium citrate and the seeds 1 into a mixed solution of cetyltrimethylammonium chloride (CTAC), reacting and centrifuging to obtain precipitates, and redissolving the precipitates into the CTAC solution to obtain seeds 2;
(3) adding CTAC, CTAB, trisodium citrate and the seeds 2 into water, and reacting to obtain seeds 3;
(4) mixing CTAC and HAuCl4Seed 3, D-type and/or L-type cysteine-leucine (CL) and trisodium citrate are added into water to react to obtain chiral or L-type cysteine-leucineNon-chiral gold nanoparticles.
Further, in the step (4), the chiral configuration of the gold nanoparticles is controlled by controlling the chiral configuration of CL; the chiral strength of the gold nanoparticles is regulated and controlled by controlling the addition of CL.
Further, in the step (4), when the amounts of the D-type CL and the L-type CL added are the same, the achiral gold nanoparticles are obtained; when D-type or L-type CL is added, chiral gold nanoparticles are obtained; the ratio of the added molar weight of the D-type or L-type CL to the mass of the chiral gold nanoparticles is 12.8 x 10-8～25.8*10-8When the mole/g is higher than the mole/g, the anisotropy factor of the chiral gold nanoparticles is 0.1-0.2.
Further, the chiral gold nanoparticles are subjected to modification treatment and then are administered.
Further, the modification of the chiral gold nanoparticles comprises the following steps:
(1) resuspending the chiral gold nanoparticles in a CTAB solution to obtain a suspension, adding methoxypolyethylene glycol thiol into the suspension, and standing;
(2) and centrifuging the solution after standing treatment, removing the supernatant, and then suspending in water to obtain a dispersion for use.
Further, in the step (1), the concentration of the cetyltrimethylammonium bromide solution is preferably 0.5 mM.
The chiral gold nanoparticles prepared by the preparation method have high-concentration CTAB remained on the surface, are washed by ultrapure water to remove the high-concentration CTAB, and then are dispersed into low-concentration CTAB to stabilize the chiral strength while dispersing the gold nanoparticles.
Further, in the step (1), the mass-to-volume ratio of the methoxypolyethylene glycol thiol to the suspension is more than 10 mg/mL.
Further, the molecular weight of the methoxypolyethylene glycol thiol is preferably 2000; the hexadecyl trimethyl ammonium bromide on the surface of the gold nanoparticle is substituted or coated by methoxy polyethylene glycol thiol, so that the biotoxicity is reduced, and the biocompatibility is improved.
Further, in the step (1), the standing time is not less than 12 h.
The invention has the beneficial effects that: according to the invention, the content of short-chain fatty acid in intestinal tracts is increased by using the chiral gold nanoparticles, the increase of the short-chain fatty acid is regulated and controlled by controlling the chirality and the strength of the gold nanoparticles, and the D-type chiral gold nanoparticles with certain chiral strength have selectivity on the improvement of different contents of the short-chain fatty acid; in addition, the chiral gold nanoparticles modified by methoxy polyethylene glycol thiol have good biocompatibility and stability, do not damage organisms, and have good application prospects in the aspects of treating intestinal diseases, immune diseases and the like.
Drawings
FIG. 1 is a scanning electron micrograph of L-CL gold nanoparticles;
fig. 2 is a graph of the ultraviolet-visible absorption spectrum and Circular Dichroism (CD) spectrum of L-CL gold nanoparticles with g being 0.2;
FIG. 3 is a scanning electron micrograph of D-CL gold nanoparticles;
fig. 4 is a graph of the uv-vis absorption spectrum and CD spectrum of D-CL gold nanoparticles with g being 0.2;
FIG. 5 is a scanning electron micrograph of D/L-CL gold nanoparticles;
fig. 6 shows the adjustment of the content of acetic acid, propionic acid, isovaleric acid and butyric acid in intestinal tract by the chiral/achiral nanoparticles.
Detailed Description
The present invention is further described below in conjunction with the following figures and specific examples so that those skilled in the art may better understand the present invention and practice it, but the examples are not intended to limit the present invention.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items.
The experimental methods used in the following examples are conventional methods unless otherwise specified, and materials, reagents and the like used therein are commercially available without otherwise specified.
Example 1 preparation of D-Au nanoparticles with g ═ 0.1
In this example, D-Au nanoparticles with an anisotropy factor (g) of 0.1 were prepared by the following specific steps:
(1) 0.6mL of 10mM NaBH4 was dissolved in 4.75mL of ultrapure water, followed by addition of 250. mu.L of 10mM HAuCl4 and 5mL of 200mM CTAB aqueous solution in this order, and reaction was carried out at 27 ℃ for 3 hours to obtain seed 1;
(2) to 2mL of 0.5mM HAuCl4Adding 1.5mL of 100mM trisodium citrate and 100 μ L of seed 1 into 2mL of 200mM CTAC mixed solution, reacting for 10min, centrifuging at 14500rpm for 30min to obtain precipitate, and re-dissolving the precipitate into 1mL of 200mM CTAC solution to obtain seed 2;
(3) 0.75mL of 200mM CTAC, 0.5mL of 100mM CTAB, 1mL of 100mM trisodium citrate, and 20. mu.L of seed 2 were added in this order to a clean tube containing 0.75mL of ultrapure water, and reacted at room temperature for 2 hours to obtain seed 3;
(4) to a clean tube containing 3.05mL of ultrapure water, 1.52mL of 100mM CTAC/300. mu.L of 10mM HAuCl was added4150 μ L of seed 3, 1.5 μ L of 3mM D-cysteine-leucine (D-CL) and 280 μ L of 100mM trisodium citrate were reacted at 37 ℃ for 1h to obtain 35mg of D-Au nanoparticles with g ═ 0.1.
Example 2 preparation of D-Au nanoparticles with g ═ 0.2
In this example, D-Au nanoparticles were prepared in a manner such that g ═ 0.2, the preparation process was identical to that of example 1, and only the amount of D-CL added in step (4) of example 1 was changed, and 3 μ L of D-CL was added to the nanoparticles to prepare D-Au nanoparticles.
And (3) performing scanning electron microscope, ultraviolet-visible absorption and CD characterization on the D-Au nano particles.
As shown in fig. 1, the prepared gold nanoparticles have chiral characteristics; fig. 2 shows an absorption spectrum (dotted line) and a CD spectrum (solid line) of the D-Au nanoparticles prepared in this example, and g of the D-Au nanoparticles prepared in this example was calculated to be 0.2 according to the characterization result and the calculation formula g ═ CD value/(32980 ×. absorbance).
Example 3 preparation of L-Au nanoparticles with g ═ 0.1
This example prepared L-Au nanoparticles of g ═ 0.1, the procedure was identical to example 1, and L-Au nanoparticles of g ═ 0.1 were prepared by changing only the configuration of CL addition in step (4) of example 1, and in this example 1.5 μ L of L-CL was added.
Example 4 preparation of L-Au nanoparticles with g ═ 0.2
This example prepared L-Au nanoparticles of g ═ 0.2, the procedure was identical to example 1, and L-Au nanoparticles of g ═ 0.2 were prepared by varying only the amount and configuration of CL addition in step (4) of example 1, and by adding 3 μ L of L-CL to this example.
And performing scanning electron microscope, ultraviolet-visible absorption and CD characterization on the L-Au nano particles.
As shown in fig. 3, the prepared gold nanoparticles have chiral characteristics; fig. 4 shows an absorption spectrum (dotted line) and a CD spectrum (solid line) of the L-Au nanoparticles prepared in this example, and g of the L-Au nanoparticles prepared in this example was calculated to be 0.2 from the characterization results.
EXAMPLE 5 preparation of achiral D/L-Au nanoparticles
This example prepares achiral gold nanoparticles, the preparation process is the same as that of example 1, only the amount and configuration of CL addition in step (4) of example 1 are changed, and in this example, 1.5. mu.L of D-CL and 1.5. mu.L of L-CL are added to prepare achiral D/L-Au.
And (3) performing scanning electron microscope characterization on the achiral D/L-Au, and as shown in figure 5, the prepared gold nanoparticles have no chirality.
Example 6 Effect of gold nanoparticles of different chiralities on short-chain fatty acid content in mouse intestinal tract
Modification of chiral gold nanoparticles: the gold nanoparticles prepared in the embodiments 1 to 5 are modified, and the specific steps are as follows: 1mL of the synthesized chiral nanoparticles was centrifuged at 3500rpm for 2 min. After removing the supernatant, the pellet was resuspended in 0.5mM CTAB solution and methoxypolyethyleneglycol thiol (mPEG-SH, MW 2000) was added to a final concentration of 10mg/mL and allowed to stand overnight. The nanoparticles were centrifuged at 3500rpm for 5min, the supernatant removed and resuspended in water for use.
Performing an intragastric test on the mice by using the modified chiral gold nanoparticles: the mice fed in the same way are divided into six groups, the first group is a blank control test, and the rest five groups of mice are respectively subjected to intragastric administration by using the modified gold nanoparticle suspension prepared in the example 1-5, wherein the intragastric administration amount is 10mg/kg/day, and the intragastric administration is carried out every day for three months.
After 3 months of continuous gavage, collecting the feces of the mouse, and analyzing the relative content of short-chain fatty acids in a feces sample of the mouse by using a gas chromatography-mass spectrometer system, as shown in fig. 6, the gold nanoparticles with different chiralities and chiral strengths have influence on the generation amounts of different short-chain fatty acids (acetic acid, propionic acid, butyric acid and isovaleric acid), and the results in the figure show that the gold nanoparticles have promotion effect on the generation of the short-chain fatty acids, wherein the L-type gold nanoparticles have stronger promotion effect on the generation of the short-chain fatty acids than non-chiral gold nanoparticles, and the content of each short-chain fatty acid is higher along with the enhancement of chirality (the larger the anisotropy factor, the stronger the chirality); for the D-type gold nanoparticles, the low-chirality D-type gold nanoparticles have no obvious promotion effect on the increase of the content of most short-chain fatty acids compared with the non-chiral gold nanoparticles, but the D-type gold nanoparticles show selectivity on the promotion effect of the short-chain fatty acids along with the enhancement of chirality, and when the g of the D-type gold nanoparticles is equal to 0.2, the contents of propionic acid and isovaleric acid are promoted more obviously than that of acetic acid and butyric acid.
The above-mentioned embodiments are merely preferred embodiments for fully illustrating the present invention, and the scope of the present invention is not limited thereto. The equivalent substitution or change made by the technical personnel in the technical field on the basis of the invention is all within the protection scope of the invention. The protection scope of the invention is subject to the claims.
Claims (10)
1. An application of chiral gold nanoparticles in improving the content of short-chain fatty acids in intestinal tracts.
2. The application of the chiral gold nanoparticles to improving the content of short-chain fatty acids in intestinal tracts according to claim 1, wherein the chiral nanoparticles are D-type and/or L-type.
3. The use of chiral gold nanoparticles according to claim 1 for increasing the content of short-chain fatty acids in intestinal tract, wherein the short-chain fatty acids comprise one or more of acetic acid, propionic acid, butyric acid and isovaleric acid.
4. The application of the chiral gold nanoparticles in improving the content of short-chain fatty acids in intestinal tracts according to claim 1, wherein for chiral gold nanoparticles with the same configuration, the increase of the short-chain fatty acids in the intestinal tracts is increased along with the increase of the g value when the anisotropy factor is 0< g < 0.2.
5. The application of the chiral gold nanoparticles to improving the content of short-chain fatty acids in intestinal tracts according to claim 1, wherein the chiral gold nanoparticles are synthesized by the following steps:
(1) reacting NaBH4Dissolving in water, sequentially adding HAuCl4Reacting with CTAB water solution to obtain seed 1;
(2) to HAuCl4Adding trisodium citrate and the seeds 1 into the CTAC mixed solution, reacting and centrifuging to obtain precipitates, and redissolving the precipitates into the CTAC solution to obtain seeds 2;
(3) adding CTAC, CTAB, trisodium citrate and the seeds 2 into water, and reacting to obtain seeds 3;
(4) mixing CTAC and HAuCl4And adding the seed 3, D-type and/or L-type cysteine-leucine and trisodium citrate into water, and reacting to obtain the chiral or non-chiral gold nanoparticles.
6. The application of the chiral gold nanoparticles in improving the content of short-chain fatty acids in intestinal tracts according to claim 5,the method is characterized in that in the step (4), when the amounts of the added D-type cysteine-leucine and the added L-type cysteine-leucine are the same, the achiral gold nanoparticles are obtained; when D-type or L-type cysteine-leucine is added, chiral gold nanoparticles are obtained; the ratio of the added molar weight of the D-type or L-type cysteine-leucine to the mass of the chiral gold nanoparticles is 12.8 x 10-8～25.8*10-8When the mole/g is higher than the mole/g, the anisotropy factor of the chiral gold nanoparticles is 0.1-0.2.
7. The use of chiral gold nanoparticles according to claim 5 or 6 for increasing the content of short-chain fatty acids in intestinal tract, wherein the chiral gold nanoparticles are modified and then administered; the modification of the chiral gold nanoparticles comprises the following steps:
(1) resuspending the chiral gold nanoparticles in a CTAB solution to obtain a suspension, adding methoxypolyethylene glycol thiol into the suspension, and standing;
(2) and centrifuging the solution after standing treatment, removing the supernatant, and then suspending in water to obtain a dispersion for use.
8. The use of chiral gold nanoparticles according to claim 7 for increasing the content of short-chain fatty acids in intestinal tract, wherein in step (1), the concentration of CTAB solution is less than 5 mM.
9. The application of chiral gold nanoparticles to improving the content of short-chain fatty acids in intestinal tracts according to claim 7, wherein in the step (1), the mass-to-volume ratio of methoxypolyethylene glycol thiol to the suspension is more than 10 mg/mL.
10. The use of chiral gold nanoparticles for increasing the content of short-chain fatty acids in intestinal tract according to claim 7, wherein in the step (1), the standing time is not less than 12 h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111165514.9A CN113917017B (en) | 2021-09-30 | 2021-09-30 | Application of chiral gold nanoparticles in improving content of short-chain fatty acids in intestinal tract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111165514.9A CN113917017B (en) | 2021-09-30 | 2021-09-30 | Application of chiral gold nanoparticles in improving content of short-chain fatty acids in intestinal tract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113917017A true CN113917017A (en) | 2022-01-11 |
| CN113917017B CN113917017B (en) | 2022-05-31 |
Family
ID=79237943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111165514.9A Active CN113917017B (en) | 2021-09-30 | 2021-09-30 | Application of chiral gold nanoparticles in improving content of short-chain fatty acids in intestinal tract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113917017B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106924764A (en) * | 2017-04-24 | 2017-07-07 | 南京邮电大学 | A kind of preparation method and applications of the feature light sonic probe based on gold nano grain assembling |
| WO2017173453A1 (en) * | 2016-04-01 | 2017-10-05 | The Brigham And Women's Hospital, Inc. | Stimuli-responsive nanoparticles for biomedical applications |
| US20180169754A1 (en) * | 2016-12-16 | 2018-06-21 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Single-helical gold nanoparticle superstructures and methods of making |
-
2021
- 2021-09-30 CN CN202111165514.9A patent/CN113917017B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017173453A1 (en) * | 2016-04-01 | 2017-10-05 | The Brigham And Women's Hospital, Inc. | Stimuli-responsive nanoparticles for biomedical applications |
| US20180169754A1 (en) * | 2016-12-16 | 2018-06-21 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Single-helical gold nanoparticle superstructures and methods of making |
| CN106924764A (en) * | 2017-04-24 | 2017-07-07 | 南京邮电大学 | A kind of preparation method and applications of the feature light sonic probe based on gold nano grain assembling |
Non-Patent Citations (4)
| Title |
|---|
| VICTOR G 等: "Magnetic and Golden Yogurts. Food as a Potential Nanomedicine Carrier", 《MATERIALS》 * |
| ZHU SQ 等: "Orally administered gold nanoparticles protect against colitis by attenuating Toll-like receptor 4-and reactive oxygen/nitrogen species-mediated inflammatory responses but could induce gut dysbiosis in mice", 《JOURNAL OF NANOBIOTECHNOLOGY》 * |
| 王家家 等: "纳米四氧化三铁对大鼠肠道内短链脂肪酸影响", 《中国公共卫生》 * |
| 王立英 等: "金属纳米颗粒制备中的还原剂与修饰剂", 《化学进展》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113917017B (en) | 2022-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102214865B1 (en) | Phytoglycogen nanoparticles and methods of manufacture thereof | |
| CN107982534B (en) | Preparation method of chitosan/copper sulfide nano composite hollow sphere, product thereof and application thereof | |
| CN109078185B (en) | Nano photosensitizer and preparation method and application thereof | |
| JP5646505B2 (en) | Method for imparting water solubility or water dispersibility to hydrophobic cluster compounds | |
| CN115919801B (en) | Preparation method of tannic acid-zinc coordinated chitosan-selenium nanoparticle | |
| CN108403641B (en) | Drug-loaded nano material and preparation method thereof | |
| US20110262500A1 (en) | Conjugates comprising nanoparticles coated with platinum containing compounds | |
| CN113917017B (en) | Application of chiral gold nanoparticles in improving content of short-chain fatty acids in intestinal tract | |
| Staroverov et al. | Synthesis of silymarin− selenium nanoparticle conjugate and examination of its biological activity in vitro | |
| CN113855813B (en) | Preparation method and application of ROS-responsive marine fucoidin nanocarrier based on Fenton reaction and AIE effect | |
| CN112569367B (en) | 5-fluorouracil-mesoporous silica-sodium alginate drug delivery system and preparation method thereof | |
| CN112089838B (en) | Black phosphorus nanogel medicine for tumor microenvironment response and preparation method and application thereof | |
| CN110917349B (en) | Bowl-shaped ISP (internet service provider) composite functional nano particle as well as preparation method and application thereof | |
| CN114146065A (en) | Chloroquine-coated denatured albumin nano-particle for selectively resisting inflammatory cells and preparation method and application thereof | |
| CN1559614A (en) | Dolysaccharide nanometer anticancer material and its preparation method | |
| CN111184689A (en) | Self-assembled nano micelle, preparation method and application thereof | |
| CN117100872B (en) | Nano delivery carrier for targeted tumor drug delivery and application thereof | |
| CN109730976A (en) | A method of albumin nano granular is prepared based on free-radical oxidation | |
| CN113292050B (en) | Nano-selenium double-ball and preparation method thereof | |
| CN109666087A (en) | A kind of cyclodextrin derivative and the preparation method and application thereof | |
| CN104740638B (en) | Carboxylation graphene oxide that a kind of hydroxyapatite and folic acid are modified jointly and preparation method and application | |
| CN116987211B (en) | Benzimidazole acid-containing hydroxypropyl trimethyl chitosan quaternary ammonium salt derivative and preparation and application thereof | |
| CN114106298B (en) | Ferulic acid lignin micro-nano particles capable of treating colonitis and preparation method thereof | |
| CN114668771B (en) | Preparation method and application of ferritin nanoparticles loaded with adriamycin and ursolic acid together | |
| CN117643637B (en) | Controlled release carrier for improving biological accessibility of curcumin and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |